WHO GMP Pharma manufacturer in India
Nucleus Formulation Pvt.Ltd. is one of the WHO GMP Pharma manufacturer in India. Also Cater Third Party Manufacturing Facility.
Our comprehensive product portfolio includes a wide range of formulations such as tablets, capsules that meet various therapeutic needs.
The Company also has significant presence in diabetology, pain management, gynecology and anti-infective segments.
Nucleus Formulation competitive advantage stems from the advanced manufacturing facilities, extensive domestic network and a widespread global presence in ROW countries.
Nucleus Formulation strengthened position in the Indian Pharma market along with ROW market.
Nucleus Formulation in the Indian Pharmaceuticals industry by successfully implementing the concept of Contract manufacturing (CMO) business.
Key Points:
✔ WHO-GMP certified (ensures compliance with World Health Organization standards).
✔ May be a contract manufacturer for larger brands like Green Cross.
✔ Specializes in generic drugs (antibiotics, antivirals, cardiovascular meds).
Our Core Values
Group
The Nucleus Formulation is Green Cross Group Co. , founded by Mr. Dipesh Thakar, Mr. Jitendra Patel, Mr. Rutul Patel, Mr. Jayesh Pandya in Year: 2009 and currently lead is a driving force dedicated to transforming life.
Core Values
These strong pillars, the Core Values, which Nucleus believes in and constantly strives to build, are: Integrity, Passion for Excellence, Participative Decision Making, Concern for Society & Environment, Fairness with Care and Transparency.
Our Geographical Reach
Emerging markets is a mix of regulated and semi regulated markets comprising of Russia, South East Asia, Asia Pacific, Africa, Middle East, Central and South America. Nucleus Pharma’s products in the Therapeutic areas of Diabetology, Cardiovascular and Gastro products are promoted and supported by our sales and support team.
AFRICAN COUNTRIES:
Kenya
Kenya being the gateway to East African Markets is a territory of strategic significance for Nucleus. Having started our operations in 2018, the past couple of years have witnessed consolidation of the agreement efforts.
South Africa
Having received SA MCC’s approval for the manufacturing facility of Oral Solids and about 15 product registrations, Nucleus’s pathway is open to explore Africa’s sizeable and the most regulated market.
Nigeria
Extending its territorial fortification to Western Africa, Nucleus made successful forays into Nigeria, which by far is one of the biggest markets in West Africa. Having already secured registrations for a handful of its specialized products, Nucleus is all set to explore this attractive market.
ASIAN COUNTRIES:
Vietnam
Vietnam is one of the major market in the South East Asian arena for Nucleus. We started our operations in Vietnam in the year 2018.
Nucleus in Vietnam now has a mixed basket of products, with a focus on brand building to ensure long-term business & growth. In continuation of our Indian tradition, Nucleus has earned a distinct image for itself in Vietnam in the field of cardiology.
Srilanka
Nucleus’s consistent sales growth and remain committed towards providing a wide range of products to the Sri Lankan market. Nucleus is well known in the island for its cardio vascular and gastro intestinal range.
Myanmar
Nucleus Pharma initiated the marketing operations in Myanmar in 2015. We have more than 30 products registered in the country with another 10 in the pipeline. Our focus is on strengthening the product basket, creating brand equity and launching new molecules in the market.
Russia
Nucleus Pharma’s formulation into the regulated markets began with operations in the Uzbekistan in 2019. In Russian Federation, Nucleus has a wholly owned subsidiary for closer reach to the customers specific to Lamotrigine tablets. With product registrations in Russia and CIS , Nucleus has sizeable presence in therapeutic areas of Cardio Vascular, Neurology , Psychiatry and Gastroenterology
South America markets
Nucleus aims to penetrate the South American market with its high quality products and extensive product portfolio. Strong economic performance in this region is expected to fuel our growth in the coming years. In addition, recent regulatory developments will create further market opportunities in these countries, particularly for generic producers in both the private and public sectors. With over 15 registrations, Nucleus is increasing its foothold in important markets like Venezuela, Chile, Guatemala, Dominican Republic, Costa Rica.
Philippines
Nucleus Formulation in Asia has been in Philippines considering the market opportunities available in this densely populated island nation.
Contact Us
- Nucleus Formulation Pvt. ltd. – (Green Cross Group Co.)
- Address : – Plot No. 3484/3485, Phase IV, GIDC Ind. Estate, Chhatral, Tal. Kalol, DIst. Gandhinagar, Pin : 382729 India.
- WHO GMP Pharma manufacturer in India
- +91-9925469962 (Rutul Patel)
- nucleusformulation2009@gmail.com, sentonssa@gmail.com
